Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $66.1250.

Several brokerages have commented on VOR. Citigroup initiated coverage on shares of Vor Biopharma in a report on Friday, January 9th. They issued a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. cut their target price on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wedbush initiated coverage on Vor Biopharma in a research report on Tuesday, November 25th. They issued a “neutral” rating for the company. Finally, HC Wainwright lowered their target price on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, November 14th.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in the company. Ariose Capital Management Ltd bought a new position in shares of Vor Biopharma in the 3rd quarter worth about $5,368,000. Susquehanna Portfolio Strategies LLC bought a new stake in Vor Biopharma during the fourth quarter worth about $134,000. XTX Topco Ltd purchased a new stake in Vor Biopharma in the second quarter worth about $66,000. Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. Finally, Findell Capital Management LLC bought a new position in shares of Vor Biopharma during the fourth quarter valued at approximately $3,021,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Down 7.0%

Shares of VOR stock opened at $14.88 on Thursday. The firm has a market capitalization of $154.90 million, a price-to-earnings ratio of -0.04 and a beta of 1.99. The stock has a fifty day moving average of $14.21 and a 200 day moving average of $20.37. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).